New Zealand markets close in 4 hours 57 minutes

NRXP Jun 2024 2.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.05000.0000 (0.00%)
As of 09:30AM EST. Market open.
Full screen
Previous close0.0500
Open0.0500
Bid0.0000
Ask0.1000
Strike2.50
Expiry date2024-06-21
Day's range0.0500 - 0.0500
Contract rangeN/A
Volume1
Open interest456
  • PR Newswire

    /C O R R E C T I O N -- NRx Pharmaceuticals, Inc./

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of shares of its common stock (or pre-funded warrants in lieu thereof) at a public offering price of $0.30 per share, for aggregate gross proceeds of approximately $1,500,000, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-da

  • PR Newswire

    NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering of a limited number of shares. All of the shares of common stock are to be sold by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of

  • PR Newswire

    NRx Pharmaceuticals (Nasdaq:NRXP) Launches HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals," the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals, will present a corporate overview at the BIO CEO & Investor Conference, which is scheduled to take place February 26-27, 2024, at the Marriott Marquis in New York City. Presenting with him will be Matthew Duffy, the newly-appointed co-CEO of HOPE Therapeutics. The presentation wi